Linda Llewelyn - Nov 1, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role
Chief People Officer
Signature
/s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol
HCAT
Transactions as of
Nov 1, 2021
Transactions value $
-$140,147
Form type
4
Date filed
11/2/2021, 04:30 PM
Previous filing
Oct 5, 2021
Next filing
Dec 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Options Exercise $23.8K +2.2K +6.37% $10.80 36.7K Nov 1, 2021 Direct
transaction HCAT Common Stock Options Exercise $13K +1.1K +2.99% $11.78 37.8K Nov 1, 2021 Direct
transaction HCAT Common Stock Sale -$144K -2.7K -7.13% $53.49 35.1K Nov 1, 2021 Direct F1, F2
transaction HCAT Common Stock Sale -$32.4K -600 -1.71% $54.08 34.5K Nov 1, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -1.1K -13.66% $0.00 6.95K Nov 1, 2021 Common Stock 1.1K $11.78 Direct F4
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -2.2K -8.21% $0.00 24.6K Nov 1, 2021 Common Stock 2.2K $10.80 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 9, 2020, in accordance with Rule 10b5-1.
F2 Represents the weighted average sale price of the shares sold ranging from $53.05 to $54.03 per share, inclusive.
F3 Represents the weighted average sale price of the shares sold ranging from $54.06 to $54.15 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in Footnotes (2) and (3).
F4 25% of the 17,954 shares underlying the options vested in an annual installment on January 24, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on January 24, 2022.
F5 25% of the 59,351 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.